b r i e f c o m m u n i c a t i o n s
We report an allelic series of eight mutations in GATA2 underlying Emberger syndrome, an autosomal dominant primary lymphedema associated with a predisposition to acute myeloid leukemia. GATA2 is a transcription factor that plays an essential role in gene regulation during vascular development and hematopoietic differentiation. Our findings indicate that haploinsufficiency of GATA2 underlies primary lymphedema and predisposes to acute myeloid leukemia in this syndrome.
The co-occurrence of primary lymphedema with myelodysplasia progressing to acute myeloid leukemia (AML), termed Emberger syndrome (MIM614038), has been reported as a sporadic disorder but has also been observed in a limited number of kindreds 1 . The syndrome segregates as an autosomal dominant trait with incomplete penetrance, and additional features of the syndrome may include abnormalities in the lymphocyte subsets, specifically, a low CD4/CD8 ratio, immune dysfunction as evidenced by the occurrence of severe and widespread cutaneous warts and sensorineural deafness. Lymphedema consequent upon functional lymphatic hypoplasia is confined to one or both of the lower limbs and genitalia and predates the onset of hematological abnormalities. Karyotype anomalies associated with myelodysplasia include monosomy of chromosome 7, and transformation to AML is often rapid.
AML is a heterogeneous, hematological malignancy, and recent molecular genetic studies have identified recurrent somatic mutations in DNMT3A, NPM1, FLT3, TET3, IDH1 and IDH2 together with fusion proteins such as PML-RARX and CBFB-MYH11 each contributing to clonal development of subsets of the disease. Inherited predisposition to AML appears to be rare, as it has been described in very few kindreds beyond those with disorders of primary bone marrow failure and inherited defects of DNA repair. However, the delineation of the molecular genetic basis of familial forms of AML provides important insight into the molecular mechanisms underlying myelodysplasia and leukemic transformation. Germline RUNX1 haploinsufficiency underlies an autosomal dominant familial platelet disorder with propensity to myeloid malignancy (MIM601399) 2 , and inherited mutations in CEBPA (the gene encoding the transcription factor CCAAT/enhancer binding protein α (C/EBPα)) have also been identified in a small number of families with AML 3 . Both RUNX1 and C/EBPα are transcription factors central to the development of normal hematopoiesis, and somatic mutations in both genes have been identified in sporadic AML 4, 5 . Taken together, these findings show the critical role of dysregulation of transcription control in hematological malignancies and in AML in particular.
We sought to identify disease-causing alleles in Emberger syndrome and recruited eight unrelated affected probands to this study, one of Chinese ancestry and seven of European ancestry ( Table 1) . Two of these individuals had a family history of primary lymphedema and/or AML and six were sporadic occurrences of the disease ( Table 1) . We recruited additional family members from the two affected kindreds (Supplementary Fig. 1 ). Clinical investigation of familial cases of disease provided insight into the phenotypic variability of Emberger syndrome. Within one family (Emb-01), this variability ranged from hydrops fetalis evolving to severe bilateral lower limb lymphedema (Fig. 1a,b) with genital involvement and development of AML at 11 years of age (individual Emb-01 III-1) to an obligate carrier (her father, Emb-01 II-1) with minimal edema and a normal lymphocyte count but a low CD4/CD8 ratio (the case reports of Emb-01 are presented as case 1 in ref. 1). We undertook whole-exome sequencing of three unrelated affected individuals: one subject with sporadic disease and two subjects from kindreds with the disorder ( Table 1) . We performed whole-exome capture by in-solution hybridization followed by massively parallel sequencing (Supplementary Methods). Over 6.8 Gb of sequence was generated for each subject such that >80% of the coding bases of the GENCODE-defined exome were represented by at least 20 reads (Supplementary Table 1 ). We identified single nucleotide substitutions and small insertion and/or deletion variants using our in-house variant calling pipeline (Supplementary Methods Table 2) . We performed our analysis of the exome variant profiles under a model of a rare autosomal dominant disorder, requiring at least one previously unobserved, heterozygous nonsynonymous or splice site substitution or a coding insertion or deletion in the same gene in all three individuals, a process that highlighted GATA2 as the only candidate gene matching these criteria (Supplementary Methods and Supplementary Table 3 ). The three GATA2 variants are each predicted to lead to premature termination of the protein product with a high likelihood of functional impact (Fig. 1c) . We confirmed each of the three mutations by Sanger sequencing and assessed them in all available relatives. The two variants identified in the familial cases were shown to be transmitted across generations between affected subjects within the kindred ( Table 1) .
Mutations in
We next addressed the hypothesis that further mutant GATA2 alleles may provide the molecular genetic basis of additional cases of Emberger syndrome. We performed Sanger sequencing of the five GATA2 coding exons and their associated splice sites in five additional independent affected subjects (Supplementary Methods). We identified previously unidentified heterozygous genetic variants in all five subjects (Fig. 1c and Table 1 ). Three of these variants are predicted to lead to premature termination and hence are likely to have functional impact. The remaining two variants lead to substitution of conserved residues in a known and critical functional domain (Supplementary Methods and Supplementary Fig. 2) . The GATA family of transcription factors comprises six proteins in humans. All of these proteins have two adjacent C 4 zinc finger DNA-binding domains each containing four cysteine residues. This family of molecules controls the development of a wide range of tissues by activating and repressing transcription through the zinc-finger-mediated binding to the GATA consensus sequence motif (A/T)GATA(A/G). The p.Cys373Arg and p.Arg361Leu amino acid substitutions both reside within the second C 4 zinc-finger domain of the protein and reduce GATA2 transactivation activity in vitro (Supplementary Methods and Supplementary  Fig. 3 ). In total, we identified eight independent previously unknown GATA2 variants in 14 individuals ( Table 1) . None of the identified variants was detected in 300 unrelated control chromosomes primarily of European origin. Each variant is predicted to have substantial impact upon the function of GATA2, suggesting that dysregulation of gene expression controlled by this transcription factor is responsible for Emberger syndrome and inherited predisposition to AML. The spectrum of clinical findings across the 14 mutation carriers confirms the variable presentation of the disorder ( Table 1) .
GATA2 is expressed in hematopoietic stem cells, multipotent hematopoietic progenitors and beyond the hematopoietic system. Homozygous Gata2 knockout mice die during mid gestation from severe anemia, with levels of myeloid-erythroid progenitor cells being reduced in comparison to wild-type controls 6 . Analysis of heterozygous mice haploinsufficient for Gata2 revealed disruption of hematopoietic stem cell homeostasis within the granular macrophage progenitor compartment, which has previously been shown to be vulnerable to leukemic transformation 7 .
GATA transcription factors have previously been implicated in human cancers (reviewed in ref. 8 ). Indeed, somatic mutation of b r i e f c o m m u n i c a t i o n s GATA2 has been identified in samples from individuals with chronic myeloid leukemia undergoing blast transformation 9 . The germline defects in GATA2 underlying an inherited predisposition to AML, findings that are supported by the recent identification of a microdeletion at 3q21, encompassing 36 genes, including GATA2, in an individual with multiple congenital abnormalities and development of myelodysplasia with monosomy 7 at the age of 11 years 10 . Also of interest and relevant to our findings, GATA2 has been shown to form protein complexes with C/EBPα 11 , implicating mutation of either of the genes that encode for these transcription factors in inherited predisposition to AML. A limited number of genes have been shown to be critical for the development and maintenance of a functional lymphatic system in humans, with disruption of this system leading to primary lymphedema. These disruptions include loss-of-function mutations of the tyrosine kinase domain of VEGFR3 and defects in FOXC2, SOX18, CCBE1 and GJC2. GATA2 is known to be expressed in lymphatic, vascular and endocardial endothelial cells 12 . Neither heterozygous nor homozygous knockout mice were reported with any overt defect of the vasculature, which may suggest a level of functional redundancy of Gata2 to other Gata family members in these tissues in the mouse. However, lymphoedema is often difficult to detect in mice and may have been overlooked by gross phenotyping. We also note the described function of Gata2 in vestibular morphogenesis and growth of the semicircular canals 13 ; the relationship of these findings with the development of sensorineural deafness in 3 of the 14 mutationcarrying mice requires further investigation.
Heterozygous mutations in GATA2 have recently been identified in individuals with monocytopenia and mycobacterial infection (MonoMAC) syndrome 14 and also in individuals with dendritic cell, monocyte, B and natural killer lymphoid deficiency 15 .
Our findings show the critical role of GATA2 in the development and maintenance of the lymphatics and hematopoietic system. Further investigation is required to delineate fully the molecular and cellular mechanisms that contribute to the variable phenotypic expression of Emberger syndrome, including predisposition to AML. The identification of GATA2 as the gene responsible for this syndrome will facilitate the diagnosis and monitoring of individuals with primary lymphedema who are at an increased risk of developing this lifethreatening hematological malignancy.
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